Table 1 Single agent potency of pitavastatin and zoledronic acid in cell growth assays.

From: Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells

IC50 (µM)

Cell line

Pitavastatin (n)

Zoledronic acid (n)

HOE

0.69 ± 0.12 (6)

57 ± 6 (5)

A2780

0.67 ± 0.34 (9)

29 ± 4 (4)

CisA2780

14.0 ± 7.00 (9)

36 ± 6 (8)

Cov-318

3.40 ± 1.40 (8)

28 ± 2 (4)

Cov-362

3.10 ± 0.70 (8)

42 ± 4 (4)

Ovcar-3

4.60 ± 0.90 (6)

60 ± 4 (6)

Ovcar-4

5.20 ± 1.20 (4)

51 ± 7 (4)

Ovcar-5

2.40 ± 1.30 (9)

30 ± 6 (9)

Ovcar-8

0.40 ± 0.10 (4)

21 ± 3 (4)

Igrov-1

1.60 ± 0.10 (9)

43 ± 8 (7)

Skov-3

3.60 ± 1.00 (5)

26 ± 5 (5)

Ovsaho

0.69 ± 0.12 (5)

44 ± 7 (3)

  1. Cells were exposed to a range of concentrations of pitavastatin or zoledronic acid for 72 hr, except for the slow growing cell lines Cov-318 and Cov-362 (120 hr). The numbers of surviving cells were estimated by statin with SRB. IC50s (mean ± S.D.) were calculated from the indicated number (n) of experiments.
Back to article page